Department of Respiratory & Critical Medicine, Renmin Hospital of Wuhan University, Wuhan430060, China.
Department of Nephrology, the Third People's Hospital of Hubei Province, Wuhan430033, China.
Epidemiol Infect. 2021 Feb 17;149:e62. doi: 10.1017/S0950268821000406.
Coronavirus disease 2019 (COVID-19) is a newly emerged disease with various clinical manifestations and imaging features. The diagnosis of COVID-19 depends on a positive nucleic acid amplification test by real-time reverse transcription-polymerase chain reaction (RT-PCR) for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). However, the clinical manifestations and imaging features of COVID-19 are non-specific, and nucleic acid test for SARS-CoV-2 can have false-negative results. It is presently believed that detection of specific antibodies to SARS-CoV-2 is an effective screening and diagnostic indicator for SARS-CoV-2 infection. Thus, a combination of nucleic acid and specific antibody tests for SARS-CoV-2 will be more effective to diagnose COVID-19, especially to exclude suspected cases.
新型冠状病毒肺炎（COVID-19）是一种新发疾病，具有多种临床表现和影像学特征。COVID-19 的诊断取决于实时逆转录-聚合酶链反应（RT-PCR）对严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）的阳性核酸扩增试验。然而，COVID-19 的临床表现和影像学特征是非特异性的，SARS-CoV-2 的核酸检测可能出现假阴性结果。目前认为，检测 SARS-CoV-2 的特异性抗体是 SARS-CoV-2 感染的有效筛查和诊断指标。因此，SARS-CoV-2 的核酸和特异性抗体联合检测对 COVID-19 的诊断更为有效，尤其是对疑似病例的排除。
